NCT06388083Phase 2, phase 3Active not recruiting

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

Study sponsor: Belite Bio, Inc · BLTE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-02Estimated
Enrollment · participants60Estimated
Source updated2026-03-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Primary completion date changed

Before: Dec 2027. After: Feb 2028.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview